

AQUARIUS SURGICAL TECHNOLOGIES INC.

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2018

1. CAUTION REGARDING FORWARD-LOOKING STATEMENTS

The discussion and analysis of Aquarius Surgical Technologies Inc. (the "Corporation") may contain forward-looking statements, which involve risks and uncertainties. Actual events could differ from those anticipated in forward-looking statements. While this MD&A reflects the period ending September 30, 2018, it also addresses key events that have occurred up to and including the date of this Report.

Forward-looking statements may include sales, earnings, and profitability comments. These statements may contain words such as "anticipated", "expected", "could", "should", "may", "plans", "will", or similar expressions that are based on and arise out of our experience, our perception of trends, current conditions and expected future developments as well as other factors. By their very nature, forward-looking statements involve uncertainties and risks that the forecasts and targets will not be achieved. Readers are cautioned not to place undue reliance on forward looking statements as a number of important factors, as disclosed herein and in the Corporation's other continuous disclosure documents, could cause actual results to differ materially from those expressed in such forward looking statements.

Readers are also referred to the Corporation's documents filed on SEDAR at www.sedar.com for additional information.

2. INTRODUCTION

The following is a discussion and analysis of the Corporation's results of operations and financial condition for the period ended September 30, 2018 and should be read in conjunction with condensed consolidated interim financial statements for the period ended September 30, 2018 and the related notes thereto (the "Interim Financial Statements"). The amounts included in the following discussions are expressed in Canadian dollars (unless otherwise indicated).

3. GOING CONCERN

The Interim Financial Statements have been prepared on a going concern basis which assumes the Corporation will be able to realize its assets and discharge its liabilities in the normal course of operations. The Corporation completed the acquisition of Surgical Lasers Inc. ("SLI") with effect from March 1, 2017. The costs associated with that acquisition were allocated during the year ended March 31, 2017 and the Corporation incurred an operating loss in the year ended March 31, 2018 and in the current period. These circumstances may be considered to cast doubt on the ability of the Corporation to continue as a going concern which is dependent on the support of its creditors, the ability to obtain additional financing, and ultimately, the attainment of profitable operations. The Corporation's lenders, who are significant shareholders, have indicated that their support will continue over the forthcoming year. Significant working capital was raised during the prior fiscal year which was been further supplemented during the current period. As indicated in Note 2 to the Interim Financial Statements, those Statements do not include any adjustments to the amounts or classification of financial statement items that might be necessary if the Corporation was unable to continue as a going concern., and no adjustment has been made in those financial statements to reflect liquidation values of assets on a non-going concern basis as any such adjustment, if required, would not have a material effect on the Corporation's balance sheet.

4. SIGNIFICANT ACCOUNTING POLICIES

The financial statements of the Corporation have been prepared by management using the accounting policies and methods as outlined in Note 3 to Consolidated Financial Statements for the year ended March 31, 2018. The Interim Financial Statements have, in management's opinion, been properly prepared using judgement within reasonable limits of materiality and are in conformity with International Financial Reporting Standards ("IFRS").

5. BUSINESS OVERVIEW

(a) Discontinued Operations

As of August 1, 2014, the Corporation entered into an agreement to sell certain assets of the Corporation, namely Inventory, Equipment, Intellectual Property, Material Contracts and Customer Lists. The transaction closed on September 5, 2014 and as a result of this sale the Corporation is no longer in the distribution of industrial and consumer protective coatings, but it did retain a royalty interest on sales of the Corporation's former products for a 3 year period which ended September 5, 2017.

(b) Acquisition of Surgical Lasers Inc.

In the prior year the Corporation closed the acquisition of SLI which had been approved by shareholders at the Annual General and Special Meeting of Shareholders held on November 21, 2016

SLI, is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology, and specifically treatment of benign prostatic hyperplasia ("BPH"). Solutions comprise multiple laser systems, consumables, clinical education, service, support, and maintenance and focus on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies, and reducing total operational costs.

SLI's portable BPH laser remains the only device in its class boasting the highest output energy of any portable device and supporting all available fiber delivery systems (contact and lateral-fire for photo-selective vaporization of the prostate and end-fire for enucleation). Based on its portability, performance and its proven clinical efficacy and safety it remains the only office-based alternative, facilitating safe, efficient and effective BPH surgery in a clear operative field under both local and general anaesthetic alternatives.

The first shipment of the new Uni-core fiber (the consumable for the portable BPH laser), which offers greater performance and durability, has been successfully implemented in reference sites across the United States of America. All future production of this fiber will incorporate the Uni-core design.

The recent FDA approval and launch of the Corporation's new compact holmium laser for lithotripsy, including treatment of upper ureter and kidney stones, represents an evolution in the field of laser lithotripsy treatment, as it is the only portable laser in the world with pulse widths capable of supporting long fragmentation as well as the ability to deliver higher energy down the smaller diameter 200 micron fibers. Long fragmentation significantly reduces treatment time as it fragments the stones into pieces so small, it eliminates the requirement for basket retrieval which is typically required with other methods. Longer pulse widths also enhance control by minimizing inadvertent migration of the stone during the procedure. The ability to deliver higher energy down smaller diameter fibers, which are often required for access especially in the upper ureter, means performance is not compromised for access.

6. OVERALL PERFORMANCE RELATING TO OPERATIONS FOR PERIOD ENDING SEPTEMBER 30, 2018

Revenues from operations in the current period were \$148,884 compared to \$352,872 for the comparable period in the prior year. Cost of goods sold was \$109,270 in the period under review compared to \$296,219 in the prior year. General and administrative expenses in the period under review were \$696,667 compared to \$682,934 in the prior year. Bank charges and interest were \$6,585 in the period under review compared to \$3,865 in the prior year. Amortization expense was \$25,996 in the current period compared to \$244,946 in the prior year which included amortization of intangible in the amount of \$219,000, there was no such amount in the current period. Interest income in the current period was \$7,136 compared to \$ nil in the prior year. Royalty income in the current period was \$ nil compared to \$2,292 in the prior year.

7. SELECTED CONSOLIDATED FINANCIAL INFORMATION

Selected items from the Consolidated Balance Sheets as at September 30, 2018, September 30, 2017 and September 30, 2016:

Balance Sheet Item	30-Sep-18 \$'s	30-Sep-17 \$'s	30-Sep-16 \$'s
Cash	63,605	795,782	6,004
Accounts receivable	124,856	234,836	12,768
Inventory	803,852	716,512	-
Prepaid Expenses and deposits	39,511	14,670	-
Due from related party	170,564	121,823	-
Accounts payable	333,438	339,159	54,779
Related party advances	1,260,970	978,901	3,865,710
Deferred tax liability	-	1,150,100	-
Series "A" special shares	1	282,979	-
Shareholders Equity (Deficiency)	(53,908)	5,506,076	(3,901,575)

8. CASH

Cash on hand declined from \$795,782 in the prior year to \$63,605 in the current period.

9. ACCOUNTS RECEIVABLE

Accounts receivable decreased to \$124,856 at the end of the current period compared to \$234,836 in the prior year. Included in accounts receivable is HST receivable of \$31,480 (2017 - \$168,817).

10. INVENTORY

Inventories at the end of the current period were \$803,852 compared to \$716,512 in the prior year.

11. PREPAID EXPENSES AND DEPOSITS

Prepaid expenses and deposits at the end of the current period were \$39,511 compared to \$14,670 in the prior year.

12. DUE FROM RELATED PARTY

Due from related party at the end of the current period was \$170,564 (see Note 9(A) to the Consolidated Financial Statements); (September 30, 2017 \$121,83).

13. ACCOUNTS PAYABLE

Accounts payable increased from \$339,159 in the prior year to \$333,438 at the end of the current period.

14. RELATED PARTY TRANSACTIONS

The amount due to related party increased to \$1,260,970 at September 30, 2018 compared to \$978,901 at the end of the prior year. Please refer to Note 9(A) and (B) to the Interim Financial Statements for pertinent information pertaining to the Related Party transactions.

Aquarius Surgical Technologies Inc.
Management Discussion and Analysis
For the six months ended September 30, 2018

15. DEFERRED TAX LIABILITY

The deferred tax liability as at September 30, 2018 was \$ nil (2017 - \$1,150,100). This related to the goodwill and intangibles acquired in the SLI acquisition and was recovered in the year ended March 31, 2018.

16. SELECTED QUARTERLY FINANCIAL DATA

The table below presents selected unaudited financial data for each of the eight quarters ending September 30, 2018:

	30-Sep 2018 \$'s	30-Jun 2018 \$'s	31-Mar 2018 \$'s	31-Dec 2017 \$'s	30-Sep 2017 \$'s	30-Jun 2017 \$'s	31-Mar 2017 \$'s	31-Dec 2016 \$'s
OPERATIONS								
Sales	121,370	27,514	420,848	200,818	201,265	151,607	5,895	-
Cost of sales	83,116	26,154	344,481	222,773	187,620	108,599	5,684	-
Gross Margin	38,253	1,361	76,368	(21,955)	13,645	43,008	211	-
Expenses								
General and administrative	332,155	364,512	468,643	387,308	335,876	347,058	768,170	33,158
Impairment charge	-	-	5,759,110	-	-	-	-	-
Amortization	12,798	12,798	123,443	122,710	122,632	122,314	40,080	23
Interest and bank charges	4,034	2,551	2,650	3,016	2,203	1,662	976	541
Fair value change in Series "A" Special sh	-	-	(282,978)	-	-	-	-	-
Interest income	(7,136)	-	-	-	-	-	-	-
Royalty income	-	-	-	-	(915)	(1,677)	(1,158)	(3,061)
	341,852	379,860	6,070,868	513,034	459,796	469,358	808,068	30,661
Net Loss before taxes	(303,598)	(378,499)	(5,994,501)	(534,988)	(446,151)	(426,350)	(807,857)	(30,661)
Provision for tax recovery	-	-	1,150,100	-	-	-	-	-
Net Loss after taxes	(303,598)	(378,499)	(4,844,401)	(534,988)	(446,151)	(426,350)	(807,857)	(30,661)

Discussion of Selected Financial Data

Operations

The net loss for the three months ended September 30, 2018 was \$310,734 (\$0.02 per share) compared to loss of \$446,151 in the same period in the prior year (\$0.03 per share). For the three months ended September 30, 2018 the weighted-average number of shares outstanding was 19,381,615 (September 30, 2017 – 18,141,430).

Interest income in the current period was \$7,136 (2017 - \$ nil). Royalty Income in the current period was \$ nil (2017 - \$915). There was no Other Comprehensive Income in the current year nor in the comparative period of the prior year

17. MANAGEMENT OF CAPITAL

The Corporation defines capital that it manages as the aggregate of its loans payable, contingent consideration, share capital, contributed surplus and deficit. Its objectives when managing capital are to ensure that the Corporation will continue as a going concern, so that it can provide returns to its shareholders.

	30-Sep-18	30-Sep-17
	\$	\$
Amount due to related party	1,055,797	1,704,545
Series "A" Special Shares	1	282,979
Share capital	18,870,805	18,075,418
Contributed surplus	8,284,039	7,216,990
Deficit	(26,905,154)	(20,701,114)
Total Capital	1,305,488	6,578,818

The Corporation manages its capital structure and makes adjustments to it in light of economic conditions. The Corporation, upon approval from its Board of Directors, will make changes to its capital structure as deemed appropriate under the specific circumstances.

The Corporation is not subject to any externally imposed capital requirements or debt covenants, and does not presently utilize any quantitative measures to monitor its capital. The Corporation's overall strategy with respect to management of capital remains unchanged from the year ended March 31, 2018.

18. CONTRACTUAL OBLIGATIONS

The Corporation's only commitment consists of a lease agreement related to the Corporation's premises, commencing on July 1, 2015 and terminating on June 30, 2017 which has since been renewed to expire July 31, 2019. Under the terms of this lease, the Corporation is required to pay a proportionate share of operating costs, realty taxes and utilities, in addition to the minimum lease payments. The future minimum lease payments are shown in the table below.

2019	\$6,014
2020	3,007

The Corporation's exclusive distribution rights are dependent on the achievement of certain annual minimum purchase targets agreed between the parties from time to time. The current future minimum purchase commitments are as follows:

2019	24 units
2020	42 units
2021	60 units

19. CAPITAL RESOURCES

The Corporation does not anticipate any major expenditure on capital resources.

20. OFF-BALANCE SHEET ARRANGEMENTS

The Corporation has no off-balance sheet arrangements.

21. LONG-TERM INVESTMENTS

Woodland Biofuels Inc. ("Woodland")

The Corporation holds 112,272 shares in Woodland; further details appear in Note 10 of the Interim Financial Statements for the year ended March 31, 2018. During fiscal 2016 the Corporation wrote down the value of this investment to a nominal amount. Management is of the opinion that the full value of this investment will be realized; however, because there is no ready market for these shares, IFRS regulations require that the investment be written down to a nominal value. The Corporation will recognize the value of this investment when circumstances warrant a review.

22. RISKS AND UNCERTAINTIES

There are risks and uncertainties with the business operation and results of the Corporation. The risks noted below are not the only risks associated with the Corporation and its business, in particular the business of its wholly owned operating subsidiary, Surgical Lasers Inc. (“SLI”). Additional risks and uncertainties, including ones that the Corporation is not aware of or that the Corporation believes currently are not material, may also adversely affect the Corporation’s business.

The Corporation is in the Development Stage: The business of SLI, in particular as it is a development stage company, involves a high degree of risk, including, but not necessarily limited to, the risk factors described below.

Limited Operating History: Investment in the Corporation should be regarded as speculative, due to the nature of and the present stage of development of its business. SLI has a limited operating history. The likelihood of the success of the SLI, and thus the Corporation, must be considered in light of the risks inherent in, and the difficulties, costs, and complications encountered in the early growth stage of a business enterprise and the development and marketing of new technologies. As a result of its early growth stage of business and its limited operating history, sales and results from operations are inherently more difficult to predict, and as a result, SLI may sustain operating losses.

Uncertainty of Market Acceptance: The Corporation currently derives a substantial portion of its revenues from the sale of its portable laser systems and related fiber-optic consumables. Those sales are exclusively to sophisticated medical professionals, and are presently concentrated only in the United States of America. Because of this limited marketplace and target market concentration, a decline in the demand for the products would have a material adverse effect on the Corporation. There can be no assurance that the Corporation’s expanded marketing and sales efforts will result in increased market acceptance for the its products.

Supply Dependency: Manufacture of the products distributed by SLI is dependent on the continued efficient supply of component parts from two key exclusive suppliers, both based in Europe. The shortage of supply of any machines, parts or materials would seriously jeopardize the SLI’s ability to bring its products to market.

Dependence on Distribution Relationships: The business of SLI is dependent on the performance of its distributors.

Technological Factors: Technology of the complexity developed by SLI and its manufacturers may contain errors which, from time to time, become apparent subsequent to product introduction. To date, the cost to SLI of meeting its warranty obligations has not been significant and is, as far as possible, passed back to the respective manufacturer. However, SLI’s product operating experience is limited, and increased warranty claims could have a material adverse effect on SLI’s stature and acceptability in its marketplace.

Product Liability: The Corporation believes that it has adequate third party liability and errors and omissions insurance. To date, it has not made any claims with respect to this insurance. However, future product liability claims not covered by such insurance or in excess of the limits of such insurance could have a material adverse effect on the financial condition of the Corporation.

Technological and Product Obsolescence: The medical/surgical laser industry is characterized by rapid and significant technological changes. Current competitors or new market entrants could introduce new or enhanced products with features that render SLI’s products obsolete or less marketable. Certain competitors are significantly larger, and thus have substantially greater financial resources. The ability of SLI to compete successfully will depend in large measure on the ability of SLI and its respective exclusive manufacturers to maintain a technically superior research and development staff and to adapt to technological changes and advances in the industry, including providing for the continued compatibility of its products with evolving industry standards.

Protection of Intellectual Property: The Corporation has not applied for patents relating to the products it distributes because, at this time, the relevant technology rights belong to third parties, namely the manufacturers. SLI is preparing certain technological products and improvements that it may, if and when the opportunity arises, become the subject of application for patent or other proprietary right protection. It may be possible for competitors or customers to copy or duplicate certain aspects of the products distributed by SLI or obtain information that SLI and/or its

manufacturers regard as proprietary. Furthermore, there can be no assurance that others will not independently develop products similar to those developed or planned by SLI and its manufacturers.

Infringement of Proprietary Rights: Although the Corporation believes that the products it distributes do not infringe on the proprietary rights of others and has not received any notice of claimed infringement, certain of the products it distributes could infringe on existing proprietary rights. If any such infringement does exist, there can be no assurance that any necessary licenses or rights could be obtained on terms satisfactory to Corporation or the respective manufacturer or that necessary modification could be made to the infringing products in a timely or commercially feasible manner.

Strict regulatory environment: SLI's laser devices and fiber delivery systems require regulatory approval for commercial sale. Numerous statutes and regulations govern human testing and the manufacture and sale of medical devices in the United States, Canada and the European Union and other countries where SLI intends to market its product. Such legislation and regulation bears upon, among other things, the approval of protocols, human testing, the approval of manufacturing facilities, testing procedures and controlled research, review and approval of manufacturing, preclinical and clinical data prior to marketing approval, as well as regulation of marketing activities including advertising and labelling.

While SLI has obtained relevant regulatory approvals in the United States for its current range of key laser products, future products and future developments of existing products may require submission for further testing of which the outcome cannot be guaranteed. Any failure to obtain necessary regulatory approval in future would materially adversely affect SLI's business, financial condition and results of operations.

Dependence Upon Key Personnel: The success of the Corporation is largely dependent on the personal efforts of certain key officers and employees. The loss of any of these key individuals could have a material adverse effect on the Corporation's business and prospects. In this respect the Corporation does not currently maintain keyman insurance. All employees, as a condition of employment, have signed confidentiality and non-compete agreements.

Government Assistance: The Corporation may utilize its entitlement for government assistance under applicable plans or programs that are designed to encourage investment in technology. There can be no assurance that such assistance will be made available to the Corporation with respect to any research and development of its technologies. There can be no assurance that the Corporation's research and development efforts will qualify for such assistance. Further, should the Corporation become listed on a major exchange, the rate of tax credits available on qualifying research and development expenditures will decrease by approximately 50%, and such credits will no longer be refundable.

Risk of International Sales: The continued growth of the Corporation's business will depend to a significant extent on sales to customers located outside Canada – principally in the United States of America. The cost of supporting a widespread customer base could have a materially adverse effect on the Corporation.

Insurance costs could negatively impact profitability: The cost of insurance, including director and officer, worker's compensation, property, product liability and general liability insurance, has risen significantly in recent years and is expected to continue to increase. These increases, and the Corporation's increased risk due to increased deductibles and reduced coverages, could have a negative impact on results of operations, financial condition and cash flows.

Risk of product liability claims: The use of medical devices for treatment of humans, even after regulatory marketing clearance approval is obtained, can result in product liability claims. Product liability claims can be expensive, difficult to defend and may result in large judgments or settlements. The Corporation currently maintains product liability insurance in connection with the use of its devices but may not, in the future, be able to obtain or maintain adequate protection against potential liabilities arising from such use. If the Corporation is unable to obtain sufficient levels of insurance at acceptable cost or otherwise protect against potential product liability claims, it will be exposed to product liability claims. A successful product liability claim in excess of the Corporation's insurance coverage could harm the Corporation's financial condition, results of operations and ability to continue in business. Even if a claim is not successful, defending such a claim may be time-consuming and expensive.

Risk of use of product in unapproved circumstances: While the Corporation is prohibited by law from marketing or promoting any unapproved use of its products, physicians/clinicians in most jurisdictions, can use these products in ways or

circumstances other than those strictly within the scope of the regulatory approval. Although the product training the Corporation will provide to physicians and other health care professionals will be limited to approved uses or for clinical trials, no assurance can be given that claims might not be asserted against the Corporation if its product is used in ways or for procedures that are not approved.

Unexpected product safety or efficacy concerns: Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales, as well as product liability, consumer fraud and/or other claims. This could have a material adverse effect on the Corporation's business, financial results and operating results

Future Financing Requirements: The Corporation anticipates that it will require additional financing in the future in order to fund continued product development and marketing. There is no assurance that such financing will be available.

Foreign Exchange Rates: Substantially all of the Corporation's sales are denominated in U.S. dollars. General and Administrative costs are incurred principally in Canadian dollars, while costs of product acquisition from exclusive manufacturers in Europe are denominated in Euros. The economics of the Corporation's business may be adversely affected by fluctuations in foreign exchange rates which may adversely affect both sales and gross margins from the sales of its products.

Dilution: Calls for additional capital to develop the Corporation's business in the future may be met by issuance of common shares, leading to dilution of existing shareholder interests.

No Dividends: The Corporation has not paid any dividends with respect to its Common Shares and does not anticipate paying any dividends in the foreseeable future.

In addition to the foregoing Risks and uncertainties, there also financial risks which are discussed in detail in Note 19 to the Interim Financial Statements for the year ended March 31, 2018

23. DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

As required by National Instrument 52-109, the Corporation's Acting Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") will be filing annual and quarterly certificates of disclosure concurrent with the filing of its annual and quarterly filings.

The Board of Directors together with an independent and qualified Audit Committee provide direct oversight responsibilities for the review of the quarterly and annual financial statements.

24. STOCK EXCHANGE LISTING

Since June 21, 2017, the shares have been listed on the Canadian Securities Exchange, trading under the symbol ASTI

25. SHARE CAPITAL, WARRANTS AND INCENTIVE STOCK OPTIONS

As at September 30, 2018 there were 19,381,615 and at the date of this Report there are 19,441,371 issued and outstanding common shares (September 30, 2017 – 18,233,545).

As at September 30, 2018 and at the date of this Report there are 1,532,901 issued and outstanding Series "A" special shares (September 30, 2017 – 1,532,901).

As at September 30, 2018 and at the date of this report there are 4,437,430 issued and outstanding Class "A" Warrants (September 30, 2017 – 3,025,000) and 150,276 issued and outstanding Class "A" Brokers Warrants (September 30, 2017 – 93,780).

Aquarius Surgical Technologies Inc.
Management Discussion and Analysis
For the six months ended September 30, 2018

As at September 30, 2018 and the date of this Report there are 1,148,070 issued and outstanding Class “C” Warrants and 38,008 issued and outstanding Class “C” Brokers Warrants.

As at September 30, 2018 and at the date of this Report there are 1,460,000 issued and outstanding Incentive Stock Options to purchase common shares (September 30, 2017 – 1,450,000).

Please refer to Notes 11,12 and 21 to the Interim Financial Statements for the year ended September 30, 2018 for additional information on share capital, Warrants and Incentive Stock Options

26. ESCROW

As a condition of the closing of the acquisition of the issued shares of Surgical Lasers Inc., and in accordance with the general requirements of *National Policy 46-201*, Gordon Willox, as Vendor, entered into an Escrow Agreement pursuant to which the securities issued to him as consideration for the acquisition of Surgical Lasers Inc. were placed In Escrow. The Escrowed Securities are to be released in accordance with a timed schedule over a period of 36 months from the date upon which trading of the common shares of the Company commences. The Tables below set out (a) particulars of the securities placed in escrow and (b) the details of release from escrow.

Designation of class held in escrow	Number of securities held in escrow	Percentage of class
Common Shares	4,598,704	27.33%
Series A Special Shares	1,532,901	100%

The following Table sets out details of the Release provisions.

Release Dates	Percentage of Total Escrowed Securities to be Released		Total Number of Escrowed Securities to be Released	
	Common	Series A	Common	Series A
Listing Date	10%	10%	459,870	153,290
6 months	15%	15%	689,805	229,935
12 months	15%	15%	689,805	229,935
18 months	15%	15%	689,805	229,935
24 months	15%	15%	689,805	229,935
30 months	15%	15%	689,805	229,935
36 months	15%	15%	689,809	229,936
	100%	100%	4,598,704	1,532,901

As at March 31, 2017, all of the above securities were held in Escrow. In accordance with the provisions of the Escrow Agreement, 459,870 common shares and 153,290 Series “A” special shares were released from Escrow on June 21, 2017, being the Listing Date when the common shares commenced trading on the Canadian Securities Exchange and subsequent releases will take place at six-monthly intervals from that date as indicated in the above Table. A further 689,805 common shares and 229,935 Series “A” special shares were released from Escrow on December 21, 2017 and a further 689,805 common shares and 229,935 Series “A” special shares were released from Escrow on June 21, 2018, so that as at the date of this Report 2,759,224 common shares and 919,741 Series “A” special shares are held in Escrow.

Additional information may be found in the Corporation’s documents filed on SEDAR, at www.sedar.com.

DATED: November 29, 2018

CORPORATE PROFILE

Board of Directors

David J. Hennigar, Bedford, Nova Scotia	Director, Chairman
N. Gary Van Nest, Toronto, Ontario	Director, Vice Chairman
Gordon Willox, Newmarket, Ontario	Director
Dr. Robert Francis, Toronto, Ontario	Director
Dr. Stanley Swierzewski III, Holyoke, MA, USA	Director

Corporate Officers

N. Gary Van Nest, Toronto, Ontario	Chief Executive Officer
Gordon Willox, Newmarket, Ontario	President and Chief Technology Officer
Lorne S. MacFarlane, Dartmouth, Nova Scotia	Chief Financial Officer
Christopher H. Freeman, King City, Ontario	Secretary

Corporate Office

89 Scollard Street
Toronto, ON M5R 1G4
Tel.: (902) 496-7594
Fax: (902) 484-7599

Corporate Information

Bankers	Canadian Imperial Bank of Commerce, Woodbridge, Ontario
Lawyers	C. H. Freeman, Barrister & Solicitor, King City, Ontario
Auditors	RSM Canada LLP, Toronto, Ontario
Transfer Agent & Registrar	TSX Trust Company, Toronto, Ontario